# Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

> **NCT03992261** · PHASE4 · COMPLETED · sponsor: **Mayne Pharma International Pty Ltd** · enrollment: 24 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Halobetasol Topical Foam

## Key facts

- **NCT ID:** NCT03992261
- **Lead sponsor:** Mayne Pharma International Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-14
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992261, "Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03992261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*